展示4.8

機密

證明 的形式

此保證書或其行使或轉換的證券未根據1933年修正案的證券法（「證券法」）或任何適用的州證券法進行登記), 也不得轉讓，除非（I）按照證券法或適用的州證券法規的規定，根據註冊或免減登記或（II）在法律顧問的意見下，根據證券法或適用的州證券法規，不需要在這樣的轉讓中進行註冊。

不。O-[•]令狀

[•] 投票普通股股份

此保證（以下簡稱“權證”） 此保證於2024年7月25日（以下簡稱“初始發行日期”）由Delaware公司FORTRESS BIOTECH, INC.（以下簡稱“公司”）發行給[•]，一家[•]（以下簡稱“買方”和任何受讓人或轉讓人一起，“持有人「」或「」持有人”).

鑑於公司、購買方作爲放貸人是某項信貸協議的關聯方，該信貸協議日期爲2024年7月25日（"授信協議 (Credit Agreement)），根據該協議，公司可以從購買方和其他在場的放貸人（統稱“放貸方”）借款，放貸方可以在信貸協議簽訂之日起至到期日向公司提供最高5000萬美元的貸款；並

鑑於公司發行此權證給購買人，作爲購買人根據信貸協議放貸的先決條件。

因此現在對於良好和有價值的考慮，特此確認收到並認可，公司和買方同意如下：

第1節。定義除非在本文件中另有定義，否則大寫字母術語具有信貸協議中所載的含義（截至本文件日期的有效信息），但在本文件中使用以下術語具有以下含義：

“綜合練習 價格” 指根據以下規定行使本認股權證 第 4 節 （無論是全部還是部分）， 金額等於 (i) 當時行使本認股權證所涉標的股票數量的產品 變成這樣 第 4 節，乘以 (ii) 行使價。

“普通股等價物「公司證券」指可能使持有人隨時取得表決普通股的任何證券，包括但不限於任何債務、優先股、權利、期權、認股權證或其他證券，該等證券在任何時候可轉換爲、行使或兌換爲表決普通股，或以其他方式使持有人有權獲得表決普通股的工具。

“公允市場價” 表示，就任何安防-半導體或其他財產而言，其公允市場價值由公司董事會的獨立成員誠信判斷。如果持有人書面異議董事會對公允市場價值的計算，在收到通知後十（10）天內，而持有人和公司在持有人提出異議後的五（5）天內無法就公允市場價值達成一致，將調用《第21節》中規定的評估爭議解決程序來判斷公允市場價值。 第21節 決定公允市場價值。

“市場價格針對特定安防-半導體，在任何給定的一天，即按照常規方式報告的最後成交價，或者如果當天沒有這樣的報告成交，則在該天以常規方式收盤買盤和賣盤價格的平均值，無論哪種情況都是在適用證券所在的主要國家證券交易所上交易或被列入交易清單，或者如果未被列入交易所交易清單或者任何國家證券交易所上市，則在OTCQb、OTCQX或由OTC Markets Group Inc.或其進行繼承的類似機構維護的粉紅色開放市場上的最後一個報價買盤價。"市場價格"應在沒有參考盤後或交易時間延長的情況下確定。如果這種證券不是以上述報價的方式上市和交易，不能提供所需期間內的報價，那麼每股表決普通股的市場價格將被視爲董事會獨立成員依據公司委託的具有國家認可資格的獨立評估師或估值公司的意見以及合理可接受持有人（或如果有多個持有人，未包括任何持有公司聯屬公司的持有人利益佔多數的持有人）的善意確定的每股證券的市場公允價值。爲了確定表決普通股的市場價格，應參考發生事件的前一交易日、交易日、或者之後的時間，（i）該交易日將被視爲在表決普通股上市的交易市場通常安排的收盤時間後立即開始，或者如果交易時間較早關閉，則在該較早時間結束，（ii）該交易日將在下一個通常安排的收盤時間結束，或者如果交易在較早時間關閉，則在該較早時間結束（毋須疑義，如一個事件前確定的最後一個交易日的市場價格，而某一天的交易關閉時間爲下午4:00，指定事件發生在當天下午5:00，那麼市場價格將參照下午4:00的收盤價確定）。

“允許的交易” 意味着作爲購買企業和/或相關資產的對價或資金來源，並與員工福利 計劃和與過去董事會批准的正常業務一致的補償安排有關。

“交易日「交易日」指投票普通股在交易市場上交易的日子，如果投票普通股沒有在交易市場上交易，則指投票普通股當時交易的主要證券交易所或證券市場上的日子。

“交易市場“ 意味着NASDAQ證券交易所、紐約證券交易所或紐約證券交易所的美國交易所。

第2部分。認股權證發行; 條款作爲對方表示的信譽和對價，公司特此授予持有人從公司購買[•]全額支付且無需補繳的公司普通股股票，每股面值爲$0.001（“普通股投票權”）。通過對該認股權證行使而發行的普通股股票在此後稱爲“基礎股票”。該認股權證可以在自此日期起的七（7）年期間的任何時間內全部或部分行使，此七（7）年期的最後一天稱爲“到期日”).

第3節。 行使價格每一張基礎股票可以購買的普通股票的行使價格爲$[•]。¹， 根據調整。 第七節 ”，並可獲得額外的ADSs共計281,250股行使價格”).

第四節。行使數量：.

(a)            本認股權可由持有人於起初發行日期後及在到期日前行使，就所有或任何部分基礎股份，向公司遞交隨附於Annex A的表格形式的書面通知，連同本原始認股權和（x）支付總行使價或（y）指示公司扣除於此認股權行使時可發行的一定數目基礎股份的價值（根據適用行使日期前所結束的最後五個交易日有投票權普通股的平均市價計算）等於該總行使價（統稱為“行使數量：”，行使日期為“行使日期”）。 如果根據上述（x）款支付，行使價格將由持有人遞交一張以公司為抬頭的已認證或官方銀行支票，或者將立即可用資金匯至公司指定的帳戶。本認股權應被視為於適用行使日期行使，持有人有權收到該行使所需的基礎股份並被視為自該日擁有基礎股份的記錄持有人。當行使本認股權時，公司應於適用行使日期的兩個（2）個交易日內（“基礎股份交付日期”）, 向本認股權持有人交付（a）確認本認股權行使的總基礎股份數的聲明，以及（b）如果基礎股份以證書形式發行，則證明或證書，證明可根據此行使發行可發行的基礎股份，或（ii）如果基礎股份以無證券形式發行，則以書面確認證明此基礎股份已以持有人的名義登記。 提供 如果公司未能於交付持有人的基礎股票交付日期（在以證券形式發行的基礎股份的情況下，是交付證書，或在以非證券形式發行的基礎股份的情況下，是以書面確認）前交付證明文件，持有人將有權撤銷該行使；提供, 進一步說明持有人如果實際發行並交付予持有人的基礎股份，則需將這些基礎股份退回，並同時將已支付給公司的基礎股價總額退回給持有人，並恢復持有人根據本認股權證所需購買該等基礎股份的權利（包括發行一份證明已恢復該權利的替換認股權證）。「根據本條款持有人因此做出的撤銷不會影響持有人依據適用法律或法律與平等原則或根據第13條所擁有的其他救濟」； 第4(a)條款對此的撤銷不影響持有人依據適用法律或平等原則或 第13條 由於公司未能及時交付基本股份，故此導致本權證。如果本認股權證將行使，其中基本股份未全部包括在內，持有人要求並在交出本權證書後，公司應交付涵蓋未行使本權證之基本股份數目的新權證，該新權證在其他方面應與本權證相同。除了在中提出的事項外。 第8部分公司契約並同意，在本權證發行或行使時對任何州和聯邦發行稅支付到期款項。

¹ 認股權證設定於Tranche A結束時Fortress普通股的30日後VWAP。

(b)            In the event of any withholding of shares of Underlying Shares pursuant to Section 4(a)(y) above where the number of the Underlying Shares then issuable upon exercise of this Warrant with an aggregate value equal to the Aggregate Exercise Price is not a whole number, the number of the Underlying Shares withheld by the Company shall be rounded up to the nearest whole share, and the Company shall make a cash payment to the Holder (by delivery of a certified or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of Underlying Shares being so withheld by the Company in an amount equal to the product of (x) such incremental fraction of Underlying Shares being so withheld multiplied by (y) the value per share of Underlying Shares (determined on the basis of the average Market Price per share for the Voting Common Stock on the last five Trading Days for such stock ended immediately prior to the applicable Exercise Date).

(c)             公司不得故意實施行使本認證，而持有人不得行使本認證的權利 持有人（連同該人的附屬公司）在實施該行使之後可以有利地擁有的範圍 超過 9.99％（」最大百分比」) 在生效後立即未發行的投票普通股 這樣的練習。就上一句而言，該等有利所擁有的投票普通股的總數 個人及其附屬公司須包括行使本認股權證時可發行的投票普通股股份數目。 正在裁定該判決，但不包括可發行的投票普通股股份 (i) 行使該人及其附屬公司有利所擁有的本認證的剩餘未行使部分，以及 (ii) 行使 或轉換本公司之任何其他證券的未行使或未轉換部分由該人及其有利所擁有 受轉換限制的附屬公司（包括但不限於任何可換股票據或可換股票或認股權證） 或執行類似於本文所載的限制。除上一句所述外，就本段而言， 實惠所有權須按照《交易法》第 13 (d) 條計算。就本認證而言， 在確定投票普通股之未發行股數目時，本認股權證持有人可依據已發行的數目 表決普通股的股份，如反映在 (1) 公司表格 10-k 表格、10-Q 表格或其他表格中的最新版本 向證券交易監察委員會公開申報（視情況而定）（2）本公司最近的公開公告 或 (3) 本公司或其轉讓代理人發出的任何其他通知，其中載列出現有投票之普通股數目。 根據持有人的書面或口頭要求，公司應於五（5）個交易日內向該持有人確認編號 當時未發行的投票普通股股份的股份。此外，持有人應在本公司的書面要求下確認 該公司當時對該公司的投票普通股有關的現有利擁有權。

第5部分。無碎股在行使這項認股權或根據任何調整而發行碎股是不被允許的，而任何小數部分應向上取舍為最接近整數的股份。如果在行使或調整這項認股權時出現小數股，公司將支付給持有者該碎股的現金價值，以行使價計算。 第 7 部分，並且任何碎股都應向上取舍至最接近整數股份。如果在行使或調整這項認股權時出現碎股，公司將支付給持有人該碎股的現金價值，以行使價為基礎計算。

第六節。證券法.

(a)            Holder acknowledges that the Underlying Shares are being offered and sold by the Company in accordance with an applicable exemption or exemptions from registration under the Securities Act and that the Underlying Shares will constitute “restricted securities” as defined in Rule 144 under the Securities Act. Neither the offer and sale of this Warrant nor the Underlying Shares have been registered under the Securities Act, or any state securities laws (“Blue Sky Laws”). This Warrant has been acquired for the Holder’s own account for investment purposes and not with a current view to distribution or resale and may not be sold or otherwise transferred (i) without an effective registration statement for such Warrant under the Securities Act and such applicable Blue Sky Laws, or (ii) unless Holder shall have delivered to the Company an opinion of counsel to the effect that the Warrant or such portion of the Warrant to be sold or transferred may be sold or transferred under an exemption from such registration; provided, that, subject to applicable law, the foregoing conditions shall not apply to any transfer of this Warrant from Purchaser to any Affiliate, managed fund or account of Oaktree Capital Management, L.P.

(b)            The Company covenants and agrees that all Underlying Shares will, upon issuance and payment therefor, be legally and validly issued and outstanding, free from all taxes, liens, charges and preemptive or similar rights, if any, with respect thereto or to the issuance thereof. The Company will take all such action as may be reasonably necessary or appropriate to assure that the Underlying Shares may be issued as provided herein without violating any applicable law or regulation, or any requirements of the Trading Market upon which the Voting Common Stock may be listed.

(c)            The certificates or book entries representing the Underlying Shares will bear the following or similar legend, unless the Company determines otherwise in compliance with applicable law:

“THE SHARES OF COMMON STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT (1) IN AN OFFSHORE TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR (3) PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS.”

Section 7. Anti-Dilution Adjustments.

(a)            Stock Dividends and Splits. If the Company shall at any time prior to the expiration of this Warrant (i) subdivide the Voting Common Stock (by stock split, recapitalization, or any other similar event) into a larger number of shares, (ii) combine the Voting Common Stock (by stock split or reverse stock split, recapitalization, combination of shares, or any other similar event) or (iii) issue by reclassification of shares of Voting Common Stock any shares of capital stock of the Company (with the exception of any reclassification that constitutes a Fundamental Change, as hereinafter defined), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the effective date of the subdivision, combination or re-classification by a fraction, the numerator of which shall be the number of shares of Voting Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Voting Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the Aggregate Exercise Price shall remain unchanged. Before taking any action which would result in an adjustment in the number of Underlying Shares for which this Warrant is exercisable or to the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

(b)            Subsequent Equity Sales. If the Company, while this Warrant is outstanding, shall sell, enter into an agreement to sell, or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise Price then in effect (such lower price, the “Base Share Price” and such issuance collectively, a “Dilutive Issuance”) (it being understood and agreed that if the holder of the Voting Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Voting Common Stock at an effective price per share that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the first Dilutive Issuance at such effective price), then simultaneously with the consummation of such Dilutive Issuance, the Exercise Price shall be reduced and only reduced to equal the Base Share Price. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 7(b) in respect of an Exempt Issuance or Permitted Transaction. “Exempt Issuance” means the issuance of (x) shares of Voting Common Stock or options to employees, officers, directors or consultants of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company or (y) securities upon the exercise or exchange of or conversion of Warrants of this series and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Warrant, provided that such securities described in sections (x) and (y) above have not been amended since the date of this Warrant to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities. The Company shall notify the Holder, in writing, no later than the Trading Day following the issuance or deemed issuance of any shares of Voting Common Stock or Common Stock Equivalents subject to this Section 7(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Underlying Shares based upon the Exercise Price as adjusted in accordance with this Section 7(b) regardless of whether the Holder accurately refers to the adjusted Exercise Price in the Notice of Exercise.

(c)            During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all (or substantially all) of holders of shares of Voting Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Voting Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date as of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Voting Common Stock are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Voting Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage).

(d)            If the Company shall at any time prior to the expiration of this Warrant (in each case, occurring after the date hereof) be a party to any merger, consolidation, exchange of shares of Voting Common Stock, sale of a majority of the Voting Common Stock, sale of all or substantially all of the assets of the Company, separation, reorganization, recapitalization, winding up or liquidation of the Company, or other similar event or transaction (each, a “Fundamental Change”), as a result of which shares of Voting Common Stock shall be changed into the same or a different number or class or classes of securities of the Company or another entity, or the holders of shares of Voting Common Stock are entitled to receive cash or other property, then, upon the Exercise of this Warrant by the Holder, such Holder shall receive, for the Aggregate Exercise Price as in effect immediately prior to such Fundamental Change (subject to all other adjustments under this Warrant), the aggregate number of shares or such other securities, cash or other property which such Holder would have received if this Warrant had been exercised immediately prior to such Fundamental Change (collectively, the “Fundamental Change Receivable”), which, upon the Holder’s election, may be received net of the Aggregate Exercise Price (for the avoidance of doubt, without payment by the Holder of any cash in an amount equal to the then Exercise Price). In the case of any Fundamental Change, the successor or purchasing party of such merger, consolidation, exchange of shares of Voting Common Stock, sale of all or substantially all of the assets of the Company or reorganization (if other than the Company) shall duly execute and deliver to the Holder a supplement to this Warrant acknowledging the Company and such party’s obligations under this Section 7(d). The terms of this Warrant shall be applicable to the Fundamental Change Receivable due to the Holder upon the consummation of any such Fundamental Change.

(e)            If any event of the type contemplated by the provisions of this Section 7 but not expressly provided for by such provisions occurs, then the Board of Directors of the Company shall make an appropriate adjustment to the Exercise Price and the number of Underlying Shares issuable upon exercise of this Warrant so as to protect the rights of the Holder in a manner consistent with the provisions of this Section 7; provided that no such adjustment pursuant to this Section 7(e) shall increase the Exercise Price or decrease the number of Underlying Shares issuable as otherwise determined pursuant to this Section 7.

(f)            Not less than five (5) days prior to the record date or effective date, as the case may be, of any event which requires or might require an adjustment or readjustment pursuant to Section 7(a), Section 7(b) or Section 7(e) (each, an “Adjustment Event”), and not less than twenty (20) days prior to the record date or effective date, as the case may be, of any Fundamental Change, the Company shall give written notice of such Adjustment Event or Fundamental Change (as applicable) to the Holder or Holders, describing such Adjustment Event or Fundamental Change in reasonable detail and specifying the record date or effective date, as the case may be. Such notice shall additionally include the Company’s certification of the following computations, as applicable, each of which shall have been made by the Company in good faith: (i) in the case of an Adjustment Event, if determinable, the required adjustment and the computation thereof or, if the required adjustment is not determinable at the time of such notice, the Company shall give notice to the Holder or Holders of such adjustment and computation promptly after such adjustment becomes determinable, and (ii) in the case of a Fundamental Change, the number of shares or such other securities, cash or other property which is payable to the Holder or Holders upon exercise of this Warrant following the Fundamental Change, the computation thereof, and the computation of the then applicable Exercise Price. Except as otherwise prohibited by applicable laws, to the extent that any notice provided pursuant to this Section 7(f) contains material, non-public information regarding the Company, the Company shall disclose such information regarding the Company in a Current Report on Form 8-K and file such Current Report on Form 8-K with the SEC no later than the second Trading Day following the date such notice is delivered to the Holder.

(g)            Notwithstanding any other provision hereof, if an exercise of all or any portion of this Warrant is to be made in connection with a Fundamental Change or a public offering, such exercise may, at the election of the Holder, be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the consummation of such transaction.

(h)            At all times on and prior to the Expiration Date, the Company shall at all times reserve and keep available out of its authorized but unissued Voting Common Stock (or other equity interests then constituting Underlying Shares), solely for the purpose of issuance upon the exercise of this Warrant, the maximum number of Underlying Shares issuable upon the exercise of this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates or effectuating the book entry of uncertificated shares to execute and issue, or enter, the necessary certificates or book entries (as applicable) for the Underlying Shares upon the exercise of the purchase rights under this Warrant. The Company shall not increase the par value of any Underlying Shares receivable upon the exercise of this Warrant above the Exercise Price then in effect, and shall take all such actions within its power as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Underlying Shares upon the exercise of this Warrant.

Section 8. Transfer of Warrant. Subject to compliance with applicable federal and state securities laws, the Holder may, from time to time, transfer this Warrant or the Underlying Shares, in each case, in whole or in part, by giving the Company a written notice of the portion of the Warrant or the shares of the Underlying Shares being transferred, such notice to set forth the name, address and taxpayer identification number of the transferee, the anticipated date of such transfer, and surrendering this Warrant or the certificates or book-entry records representing shares of the Underlying Shares, as applicable, to the Company for reissuance to the transferee(s). Upon surrender of this Warrant by a Holder to the Company for transfer, in whole or in part, the Company shall issue a new warrant to such Holder in such denomination as shall be requested by such Holder covering the number of Underlying Shares, if any, in respect of which this Warrant shall not have been transferred. Such new warrant shall be identical in all other respects to this Warrant. This Warrant may be divided or combined with other Warrants upon presentation hereof at the office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with this Section 8 as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated as of the Initial Issuance Date and shall be identical to this Warrant except as to the number of Underlying Shares issuable pursuant thereto. Any transferee or subsequent Holder will provide the Company with a duly executed and completed IRS Form W-9 or applicable IRS Form W-8, and any other form or certification reasonably requested by the Company in order for the Company to comply with its obligations under applicable tax law. Any and all documentary, stamp and similar issue or transfer taxes due on any transfer pursuant to this Section 8, or on the issuance of Underlying Shares to any transferee, shall be borne by the transferor, and no such transfer or issue shall be made unless and until the Person requesting such transfer or issue has paid to the Company the amount of any such tax or has established to the satisfaction of the Company that such tax has been paid or is not payable.

Section 9. No Impairment. The Company may not, including, without limitation, by amendment of its certificate of incorporation or bylaws, or through a Fundamental Change or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and the Company shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder or Holders against impairment. Without limiting the generality of the foregoing, the Company shall take (a) all such action as may be necessary or appropriate in order that the Company may duly and validly issue fully paid and non-assessable Underlying Shares, free from any taxes, liens, charges and preemptive rights, upon the exercise of this Warrant, and (b) use its best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be necessary to enable the Company to perform its obligations under this Warrant.

Section 10. No Rights or Liabilities as a Stockholder. This Warrant shall not entitle the Holder or Holders hereof to any voting rights or other rights as a stockholder of the Company with respect to the Underlying Shares prior to the exercise of the Warrant. No provision of this Warrant, in the absence of affirmative action by the Holder or Holders to purchase the Underlying Shares, and no mere enumeration herein of the rights or privileges of the Holder or Holders, shall give rise to any liability of such Holder or Holders for the Exercise Price or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

Section 11. Representations and Warranties of the Company. The Company hereby represents and warrants:

(a)            As of the Initial Issuance Date, the Company (A) is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, (B) has all requisite power and authority to own and operate its properties, to carry on its business as now conducted and as currently proposed to be conducted, to issue and enter into the Warrant and to carry out the transactions contemplated thereby, and (C) except where the failure to do so, individually or in the aggregate, has not had, and could not be reasonably expected to have, a material adverse effect on the business, assets, financial condition or operations of the Company, is qualified to do business and, where applicable is in good standing, in every jurisdiction where such qualification is required.

(b)            This Warrant is, and any Warrant issued in substitution for or replacement of this Warrant (including pursuant to Section 15) shall be, upon issuance, duly authorized and validly issued. This Warrant constitutes, and any Warrant issued in substitution for or replacement of this Warrant shall be, upon issuance, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally and by general principles of equity.

(c)            As of the Initial Issuance Date, the execution, delivery and performance by the Company of the Warrant does not and will not (A) violate any material provision of applicable law or the organizational documents of the Company, (B) conflict with, result in a breach of, or constitute (with the giving of any notice, the passage of time, or both) a default under any material agreement of the Company or (C) result in or require the creation or imposition of any lien upon any assets of the Company.

Section 12. Successors. All the covenants and provisions of this Warrant by or for the benefit of the Company or the Holder or Holders shall bind and inure to the benefit of their respective successors and assigns.

Section 13. Survival. The rights of the Holder or Holders under this Warrant, and the covenants and agreements of the Company set forth in this Warrant for the benefit of the Holder or Holders, shall survive exercise of all or any portion of this Warrant and shall inure to the Holder or Holders of any Underlying Shares.

Section 14. Remedies. If the Company violates, breaches or defaults under this Warrant, the Holder may proceed to protect and enforce its rights by any action at law, suit in equity or other appropriate proceeding, whether for specific performance of any agreement contained in this Warrant, or for an injunction against a violation of any of the terms hereof, or in and of the exercise of any power granted hereby or by law, in each case without providing any bond or other security in connection with such action, suit or other proceeding. In case of any violation, breach or default under this Warrant, the Company shall pay to the Holder on demand all reasonable costs and expenses of enforcing the Holder’s rights under this Warrant, including, without limitation, reasonable attorneys’ fees and legal expenses.

Section 15. Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon its receipt of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Underlying Shares (and, in the case of mutilation, the surrender and cancellation of this Warrant or such stock certificate), the Company shall make and deliver to the Holder a new Warrant or stock certificate that is identical to this Warrant or to such stock certificate (as applicable).

Section 16. Taxes.

(a)            Tax Treatment. No later than sixty (60) days after the Initial Issuance Date, Oaktree Fund Administration, LLC (“Oaktree”), on behalf of the Purchaser, shall provide the Company with a valuation of the Warrant for tax purposes (the “Proposed Valuation”). If the Company disagrees with the Proposed Valuation, it shall propose reasonable comments to the Proposed Valuation within fifteen (15) days of receiving the Proposed Valuation, and Oaktree (on behalf of the Purchaser) shall consider such comments in good faith. If the parties cannot agree as to the Proposed Valuation within ninety (90) days after the Initial Issuance Date after good faith discussion, an independent valuation firm shall be engaged (at the Company’s expense) to provide the Company and the Purchaser with a final valuation of the Warrant for tax purposes (the “Final Valuation”) within thirty (30) days of its engagement, and such Final Valuation shall be binding on Purchaser and the Company for all U.S. tax purposes.

(b)            Withholding. The Company and its paying agent shall be entitled to deduct and withhold taxes on all payments and distributions (or deemed distributions) with respect to this Warrant (or upon the exercise thereof) and the Underlying Shares, in each case, to the extent required by applicable law; provided that, other than in the case of U.S. federal withholding taxes, the Holder has received written notice from the Company advising it of the availability of any exemption or reduction and containing all applicable documentation. To the extent that any amounts are so deducted or withheld, such deducted or withheld amounts shall be treated for all purposes of this Warrant as having been paid to the Person in respect of which such deduction or withholding was made. In the event the Company previously remitted any amounts to a Governmental Authority on account of taxes required to be deducted or withheld in respect of any payment or distribution (or deemed distribution) with respect to this Warrant (or upon the exercise thereof) or the Underlying Shares, the Company shall be entitled (i) to offset any such amounts against any amounts otherwise payable in respect of this Warrant or the Underlying Shares, any Underlying Shares otherwise required to be issued upon the exercise of this Warrant or any amounts otherwise payable in respect of this Warrant received upon the exercise of this Warrant, or (ii) to require the Person in respect of whom such deduction or withholding was made to reimburse the Company for such amounts.

Section 17. Article and Section Headings. Numbered and titled article and section headings are for convenience only and shall not be construed as amplifying or limiting any of the provisions of this Warrant.

Section 18. Notice. Any and all notices, elections or demands permitted or required to be made under this Warrant shall be in writing, signed by the party giving such notice, election or demand and shall be delivered in accordance with the notice provisions in the Credit Agreement.

Section 19. Severability. If any provisions(s) of this Warrant or the application thereof to any person or circumstances shall be invalid or unenforceable to any extent, the remainder of this Warrant and the application of such provisions to other persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by law.

Section 20. Entire Agreement. This Warrant and between the Company and the Holder represents the entire agreement between the parties concerning the subject matter hereof, and all oral discussions and prior agreement are merged herein.

Section 21. Valuation Dispute Resolution. In the case of any dispute as to the determination of any amount or valuation hereunder or in connection with the amount or value of any Voting Common Stock or Underlying Shares to be issued, withheld or otherwise determined, the calculation of the Aggregate Exercise Price or any other computation or valuation required to be made hereunder or in connection herewith, in the event the Holder, on the one hand, and the Company, on the other hand, are unable to settle such dispute within five (5) Trading Days, then either party may elect to submit the disputed matter(s) for resolution by an accounting firm of nationally recognized standing as may be mutually agreed upon by the Holder and the Company. Such firm’s determination of such disputed matter(s) shall be binding upon all parties absent demonstrable error, and the Company and the Holder shall each pay one half of the fees and costs of such firm.

Section 22. Governing Law. This Warrant and the rights and obligations of the parties hereunder, and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Warrant and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.

Section 23. Jurisdiction; Waiver of Venue; Service of Process.

(a)            Each party hereto irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against any other party hereto in any way relating to this Warrant or the transactions relating hereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof; and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

(b)            Each party hereto irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement in any court referred to in paragraph (a) of this Section 22. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

(c)            Each party hereto irrevocably consents to service of process in the manner provided for notices in Section 18.

Section 24. Amendment. No amendment or modification hereof shall be effective except in a writing executed by the Company and the Holder.

Section 25. Counterparts. This Warrant may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same Warrant.

Section 26. Waiver of Jury Trial. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS WARRANT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 26.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have set their hands as of the date first above written.

[Signature Page to Warrant]

Annex A

NOTICE OF EXERCISE

TO:          FORTRESS BIOTECH, INC.

(1)   The undersigned hereby elects to purchase ________ Underlying Shares of the Company pursuant to the terms of the attached Warrant originally issued on July 25, 2024, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2)   Payment shall take the form of (check applicable box):

¨ in lawful money of the United States; or

¨ the cancellation of such number of Underlying Shares as is necessary, in accordance with the formula set forth in Section 4(a), to exercise this Warrant with respect to the maximum number of Underlying Shares purchasable pursuant to the cashless exercise procedure set forth in Section 4(a).

(3)   Please issue said Underlying Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Underlying Shares shall be delivered to the following DWAC Account Number:

_______________________________

_______________________________

_______________________________

(4)            Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity: ______________________________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: ________________________________________________________________________

Name of Authorized Signatory: __________________________________________________________________________________________

Title of Authorized Signatory: ___________________________________________________________________________________________

Date: ______________________________________________________________________________________________________________